AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03460925 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT plus chemotherapy
Description: Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox
Study NCT04798313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW031
Description: Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.
Study NCT04798313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
Study NCT03550742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fuco-N-Tetraose
Description: Daily bolus of Fuco-N-Tetraose
Study NCT04178135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rLH
Description: rLH supplement from day 1 of stimulation
Study NCT04178135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rLH
Description: rLH supplement from day 6 of stimulation
Study NCT04485234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Coronary Flow Reserve, Microvascular resistance
Description: Calculation of the resting mean distal coronary to aortic pressure ratio (resting Pd/Pa), fractional flow reserve (Pd/Pa at hyperemia), Coronary flow reserve (peak flow/resting flow), microvascular resistance (Pd/flow).
Study NCT02375204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel
Description: IV
Study NCT02375204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ifosfamide
Description: IV
Study NCT02375204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: IV
Study NCT02375204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pegylated G-CSF
Description: IV
Study NCT02375204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: IV
Study NCT02375204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: IV
Study NCT02375204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etoposide phosphate
Description: IV
Study NCT02375204 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: stem cell reinfusion
Description: surgical procedure
Study NCT01195831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xamiol® gel
Description: Once daily application
Study NCT01195831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol scalp solution
Description: Twice daily application
Study NCT01208701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Zarator, 80 mg pr day for 5 days
Study NCT01208701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unikalk
Description: 1 tablet Unikalk pr day for 5 days
Study NCT00425711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
Study NCT03587571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical intervention
Description: Open reduction and plate osteosynthesis.
Study NCT04638868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microsieve device
Description: Both portal venous and peripheral blood will be processed through a label-free size-based silicon microsieve microfiltration device, which will isolate both epithelial-type and mesenchymal-type pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
Study NCT04638868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cell surface marker-based platform
Description: Both portal venous and peripheral blood will be processed through a cell surface marker-based platform, which contains antibodies for epithelial cell markers on pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
Study NCT04571918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodegradable spacer
Description: Implantation of a biodegradable balloon used as a subacromial spacer.
Study NCT04571918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement and biceps tenotomy
Description: Surgery with arthroscopic debridement and biceps tenotomy
Study NCT04571918 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement and biceps tenotomy
Description: Surgery with arthroscopic debridement and biceps tenotomy
Study NCT01692223 — intervention group
Intervention type: BEHAVIORAL
Intervention: qualitative interviews
Description: A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety \& Depression Scale (HADS), revised Impact of Events Scale (IES-R), \& a questionnaire about their health behaviors, to establish baseline distress levels \& health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider \& discuss resultant therapeutic \& management recommendations for the participants \& their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
Study NCT02211183 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Best Repair of torn Rotator Cuff
Study NCT02211183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InSpace™ system
Study NCT02670915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study NCT02670915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study NCT02606214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TBA-354 Placebo
Study NCT02670915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study NCT02670915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study NCT02610205 — intervention group
Intervention type: OTHER
Intervention: caring touch
Description: The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
Study NCT02021825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mitoxantrone
Description: The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
Study NCT00284739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: 2mg or 4mg given twice daily for three days into loculated abscess
Study NCT00284739 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline injection twice daily for three days
Study NCT04393077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: EFT application was started by showing the meridian points to the participants through the picture. It was advised that these points should be clicked with the index finger and middle finger without hurting, but with certain strokes, and it was ensured that they understood the regions by showing and applying them. Then, the following basic steps, which should be followed by the EFT session (four in total lasting 20 minutes), were carried out in succession with the researcher.
Study NCT04315493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib maleate fasted in P1, low-fat diet in P2
Description: pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
Study NCT04315493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib maleate low-fat diet in P1, fasted in P2
Description: pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
Study NCT01407315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoMenDay
Description: Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once.
Study NCT01407315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoMenDay
Description: Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice.
Study NCT03913312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unrelated cord blood
Description: Unrelated cord blood comes from Shandong cord blood bank. TNC>1.5\*107/kg;HLA 4-5/6
Study NCT00243529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell vaccine
Study NCT01985373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin infusion
Description: Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
Study NCT00243529 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous dendritic cell vaccine
Study NCT04004377 — intervention group
Intervention type: OTHER
Intervention: Scale of quality life
Description: The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life.
Study NCT01225757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: Echocardiography will be utilized during the procedure to guide fluid management.
Study NCT01225757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: Echocardiography will be utilized during the procedure to guide fluid management.
Study NCT03833817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking about Cancer (TAC)
Description: The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
Study NCT01692002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium propionate
Description: Sodium propionate capsule or tablet
Study NCT01692002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Placebo capsule or tablet
Study NCT01692002 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Oral glucose tolerance test
Study NCT01692002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Study NCT01692002 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous glucose tolerance test.
Study NCT01692002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous glucose tolerance test.
Study NCT00818207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Full Smoking Cessation Treatment Coverage (100%)
Description: This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
Study NCT00818207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Smoking Cessation Treatment Coverage (0%)
Description: None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
Study NCT03258632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)
Description: Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
Study NCT03411577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Study NCT04172701 — intervention group
Intervention type: DRUG
Intervention: Long-acting Muscarinic Antagonists (LAMA)
Description: drug
Study NCT04172701 — intervention group
Intervention type: DRUG
Intervention: Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)
Description: drug
Study NCT03185234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: 2 mA, 10 min, 5 sessions
Study NCT03185234 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham stimulation, 10 min, 5 sessions
Study NCT03297528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
Study NCT03820934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan and Fibrosure
Description: Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
Study NCT02363608 — intervention group
Intervention type: OTHER
Intervention: standard post surgery care
Study NCT02363608 — intervention group
Intervention type: BEHAVIORAL
Intervention: Caring Canine program
Description: The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
Study NCT02363608 — intervention group
Intervention type: BEHAVIORAL
Intervention: baseline and post assessment
Description: The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
Study NCT03437317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Retraining
Description: Participants viewed faces varying in their expression of anger and were asked to identify if the face was angry or neutral via button press. Participants were provided with feedback if their categorization of the face as neutral or angry was correct. Each participant was assigned 4 levels of angry faces based on their decision point of anger detection in faces. Faces were selected based on the closest existing anger morph to the category boundary; for example, a decision point of 40% anger was closest to the 38% anger face, and so the faces used would have been 17%, 31%, 45%, and 59% anger. For this example, responses of neutral to the 31% angry face would be marked as correct, whereas a similar response to the 45% angry face would be incorrect, as it was above their decision point.
Study NCT03437317 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Gender Discrimination
Description: Participants viewed faces varying in their expression of anger and were asked to identify if the face was male or female via button press.
Study NCT00451308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of labor with foley balloon - 60cc of saline
Description: 60 cc of fluid
Study NCT02168881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Study NCT02168881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Study NCT00451308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction of labor with foley balloon with 30cc
Description: 30cc of saline in foley
Study NCT04995991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RRT rhythm only
Description: RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.
Study NCT04995991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RRT rhythm + visual cue
Description: RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
Study NCT00376727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
Study NCT00376727 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: molecular diagnostic method
Description: Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
Study NCT00376727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Peripheral Blood Mononuclear Cells (PBMC)
Study NCT00376727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Cetuximab Pharmacodynamics
Study NCT03267108 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: INOpulse®
Description: Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
Study NCT03267108 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
Study NCT03267108 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Open Label Extension
Description: Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.